Bevatas 100 Mg Injection

✅ Key Benefits

• Anti-angiogenic action helps starve tumors of blood supply

• Combination therapy option—boosts outcomes with chemo or targeted regimens

• FDA/EMA-backed efficacy in several solid tumor types

• Vial presentation allows dose adjustment based on patient weight

• Reduces disease progression and improves survival in specific cancers

🎯 How to Use

1. Administer intravenously in hospital/clinic by a qualified provider.

2. Dosage is weight-based (e.g., 5–15 mg/kg every 2–3 weeks) per oncologist’s plan.

3. Premedicate and monitor for infusion reactions during administration.

4. Track blood pressure and proteinuria regularly during treatment.

5. Use full prescribed duration, often until progression or unacceptable side effects.

⚠️ Precautions

• Oncology prescription only—administered in clinic

• Monitor for hypertension, bleeding, clotting, impaired wound healing

• Delayed surgery may be required—stop bevacizumab ≥6 weeks pre-op

• Avoid pregnancy/breastfeeding during therapy; use contraception

• Report any signs of GI perforation, hemorrhage, or proteinuria

🤕 Possible Side Effects

• Common: Elevated blood pressure, fatigue, headache, nosebleeds

• Less common: Proteinuria, delayed wound healing, rash

• Serious: GI perforation, serious bleeding, thromboembolism, severe hypertension—seek immediate care

❓ Frequently Asked Questions (FAQs)

Q. What cancers does Bevatas treat?
A. It’s used for metastatic colorectal, non-small cell lung, renal, ovarian cancers, and glioblastoma in combination with standard therapy.

Q. How is it administered?
A. Intravenously every 2–3 weeks, according to oncology protocols.

Q. Are any tests needed before use?
A. Yes—blood pressure, urine protein, and pre-infusion labs are required before each dose.

Q. Can it be used during pregnancy?
A. No—avoid during pregnancy due to risks to the fetus.